Laia Crespo, PhD, joined Sanofi Ventures in 2018 as a partner. She focuses on biotech investments and company creation. Prior to Sanofi, she served as investment director for Ysios Capital, where she led investments and served on the board of multiple early stage biotech companies. Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company part of the Johnson & Johnson group, where she assessed commercial and scientific licensing opportunities. Previously she worked as a researcher in the UK at Spirogen (now AstraZeneca), Medivir, and UCB-Celltech.

Laia’s active investments include Muna Therapeutics, NodThera, OMass Therapeutics, QurAlis, and Therini Bio. Previous investments and board roles include Lava Therapeutics (LVTX).

Laia earned a PhD with honors and master’s in science in chemistry from the University of Barcelona, where she also earned her undergraduate degree in chemistry. She completed an MBA from the Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare, and finance.